Microbiome sequencing service involves the analysis of the microbial communities present in and on the human body. These services help gain a deeper understanding of the composition and function of the human microbiome and its association with various health conditions. They assist in identifying microbes linked with certain diseases and developing microbiome-based therapeutics.

Global microbiome sequencing service market is estimated to be valued at USD 1.97 Bn in 2024 and is expected to reach USD 4.13 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.1% from 2024 to 2031.

The Microbiome Sequencing Service Market Demand is driven by rising investments in metagenomics research activities and advancements in next-generation sequencing technologies. Metagenomics techniques allow comprehensive assessment of the human microbiome, aiding the development of potential therapies for various chronic diseases like obesity, diabetes, and gastrointestinal disorders. They offer higher sensitivity, cost-effectiveness, and throughput needed for large cohort studies compared to culture-based methods. Growing initiatives by private and public organizations to sequence microbial communities are expected to boost market growth during the forecast period.

Key Takeaways
Key players operating in the microbiome sequencing service market are Microbiome Insights Inc., Baseclear B.V., Clinical Microbiomics A/S, Mérieux NutriSciences Corporation, MR DNA, Zymo Research Corporation, Metabiomics Corp., uBiome, Inc., Microbiome Therapeutics Innovation Group, Locus Biosciences, Inc., OpenBiome, Shanghai Ruiyi Biotechnology Co., Ltd., Resphera Biosciences, LLC, Molzym GmbH Co. KG, BioSpherex LLC, and Diversigen.

Get More Insights on- Microbiome Sequencing Service Market